There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), ...

Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush ...

Stock analysts at Leerink Partnrs dropped their FY2025 EPS estimates for shares of Mersana Therapeutics in a note issued to ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

Mersana Therapeutics (NASDAQ:MRSN) is scheduled to announce Q4 earnings results on Monday, March 3rd, before market open. The consensus EPS Estimate is -$0.17 (-6.3% Y/Y) and the consensus Revenue ...

Mersana Therapeutics, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has received a notification from The Nasdaq Stock Market LLC regarding non-compliance with the exchange's ...

The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock ...

for new ways to help/heal his people,’’ Romo said. “This was quite a blessing, as being a member of this ACT cohort can really facilitate advancing new therapeutics to help people in need. This ...

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Archived replays will be available for approximately 90 days following the events. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody ...